High-dose chemotherapy for Ewing sarcoma and Rhabdomyosarcoma: A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party

Patients with high-risk or metastatic Ewing sarcoma (ES) and rhabdomyosarcoma (RMS) have a guarded prognosis. High-dose chemotherapy (HDT) with autologous stem cell transplant (ASCT) has been evaluated as a treatment option to improve outcomes. However, survival benefits remain unclear, and treatment is associated with severe toxicities.

Citation:
Ramamurthy A, Connolly EA, Mar J, ……. Phillips MB, Winstanley M, et al. High-dose chemotherapy for Ewing sarcoma and Rhabdomyosarcoma: A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party. Cancer Treat Rev. 2024;124

Keywords:
Autologous stem cell transplant; Ewing Sarcoma; Guidelines; High dose chemotherapy; Paediatric oncology; Rhabdomyosarcoma; Sarcoma

Abstract:
Patients with high-risk or metastatic Ewing sarcoma and rhabdomyosarcoma have a guarded prognosis. High-dose chemotherapy with autologous stem cell transplant has been evaluated as a treatment option to improve outcomes. However, survival benefits remain unclear, and treatment is associated with severe toxicities.